Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price traded up 6.3% during mid-day trading on Wednesday . The company traded as high as $7.53 and last traded at $7.45, 26,063,727 shares were traded during trading. An increase of 69% from the average session volume of 15,405,729 shares. The stock had previously closed at $7.01.
A number of equities research analysts recently issued reports on the stock. Mizuho set a $11.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, June 17th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Friday, July 5th. Wolfe Research assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, July 19th. They set a “peer perform” rating and a $9.00 target price for the company. UBS Group set a $8.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, August 16th. Finally, Raymond James dropped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Six investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $13.04.
The business’s fifty day simple moving average is $7.80 and its 200 day simple moving average is $12.31. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The stock has a market cap of $7.75 billion, a P/E ratio of 2.52, a price-to-earnings-growth ratio of 0.74 and a beta of 1.64.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. The company’s revenue was down 7.7% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post 2.25 earnings per share for the current fiscal year.
In related news, Director Sol J. Barer acquired 111,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were purchased at an average price of $8.98 per share, with a total value of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.49% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of TEVA. First Interstate Bank bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $28,000. Pacer Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. Kavar Capital Partners LLC bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $35,000. G&S Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries by 99.4% in the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock valued at $37,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after purchasing an additional 945 shares during the last quarter. 63.05% of the stock is currently owned by institutional investors.
Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: What are the advantages of the Stochastic Momentum Index?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.